139 related articles for article (PubMed ID: 26688384)
1. Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study.
Frederiksen H; Farkas DK; Christiansen CF; Larsen TS; Hasselbalch HC; Stentoft J; Sørensen HT
Lancet Haematol; 2015 Jul; 2(7):e289-96. PubMed ID: 26688384
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.
Frederiksen H; Farkas DK; Christiansen CF; Hasselbalch HC; Sørensen HT
Blood; 2011 Dec; 118(25):6515-20. PubMed ID: 22039256
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study.
Farmer S; Horváth-Puhó E; Vestergaard H; Hermann AP; Frederiksen H
Br J Haematol; 2013 Dec; 163(5):603-10. PubMed ID: 24111669
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasms cause glomerulopathy.
Said SM; Leung N; Sethi S; Cornell LD; Fidler ME; Grande JP; Herrmann S; Tefferi A; D'Agati VD; Nasr SH
Kidney Int; 2011 Oct; 80(7):753-9. PubMed ID: 21654720
[TBL] [Abstract][Full Text] [Related]
6. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
7. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
8. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
9. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative disorders in the department of Côte d'Or between 1980 and 1986.
Heudes D; Carli PM; Bailly F; Milan C; Mugneret F; Petrella T
Nouv Rev Fr Hematol (1978); 1989; 31(5):375-8. PubMed ID: 2587208
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
12. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
13. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
14. Interferon in the treatment of myeloproliferative diseases.
Silver RT
Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
[TBL] [Abstract][Full Text] [Related]
15. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
Tovar-Bobadilla JL; Ortiz-Hidalgo C
Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
[TBL] [Abstract][Full Text] [Related]
16. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
19. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.
Cervantes F; Tassies D; Salgado C; Rovira M; Pereira A; Rozman C
Acta Haematol; 1991; 85(3):124-7. PubMed ID: 2042444
[TBL] [Abstract][Full Text] [Related]
20. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
